Daniel T. Roble
Former positions of Daniel T. Roble
| Companies | Position | End |
|---|---|---|
Point Therapeutics, Inc.
 Point Therapeutics, Inc. BiotechnologyHealth Technology Point Therapeutics, Inc. develops drugs for the treatment of cancer and blood cell disorders. The company's PT-100 (talabostat) treats anemia and neutropenia (low levels of white blood cells), which can be caused by diseases or medical treatments, such as chemotherapy. The drugs stimulate production of proteins that build up the body's immune system against malignant tumors. Point Therapeutics, Inc. is located in Boston, MA. | Director/Board Member | 2008-02-12 |
DARA BioSciences, Inc. /Old/
 DARA BioSciences, Inc. /Old/ Pharmaceuticals: MajorHealth Technology DARA BioSciences, Inc. develops therapeutic and medical technologies and devices. It also provides treatment for metabolic diseases and central nervous system disorders . The company was founded by Steve Gorlin in July, 2002 and is headquartered in Raleigh, NC. | Director/Board Member | 2008-02-12 |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Point Therapeutics, Inc.
Point Therapeutics, Inc. BiotechnologyHealth Technology Point Therapeutics, Inc. develops drugs for the treatment of cancer and blood cell disorders. The company's PT-100 (talabostat) treats anemia and neutropenia (low levels of white blood cells), which can be caused by diseases or medical treatments, such as chemotherapy. The drugs stimulate production of proteins that build up the body's immune system against malignant tumors. Point Therapeutics, Inc. is located in Boston, MA. | Health Technology |
DARA BioSciences, Inc. /Old/
DARA BioSciences, Inc. /Old/ Pharmaceuticals: MajorHealth Technology DARA BioSciences, Inc. develops therapeutic and medical technologies and devices. It also provides treatment for metabolic diseases and central nervous system disorders . The company was founded by Steve Gorlin in July, 2002 and is headquartered in Raleigh, NC. | Health Technology |
- Stock Market
- Insiders
- Daniel T. Roble